华润医药(03320.HK) 宣布,集团旗下附属双鹤药业(海南)收到国家药品监督管理局颁发的注射用吗替麦考酚酯《药品补充申请批准通知书》,该药品通过仿制药注射剂一致性评价。 注射用吗替麦考酚酯适用于预防接受同种异体肾移植或肝移植患者的急性器官排斥反应。根据全球71个国家药品销售数据库显示,2025年注射用吗替麦考酚酯全球销售额为2,544.69万美元。根据米内网数据显示,2025年国内医疗市场和...
Source Link华润医药(03320.HK) 宣布,集团旗下附属双鹤药业(海南)收到国家药品监督管理局颁发的注射用吗替麦考酚酯《药品补充申请批准通知书》,该药品通过仿制药注射剂一致性评价。 注射用吗替麦考酚酯适用于预防接受同种异体肾移植或肝移植患者的急性器官排斥反应。根据全球71个国家药品销售数据库显示,2025年注射用吗替麦考酚酯全球销售额为2,544.69万美元。根据米内网数据显示,2025年国内医疗市场和...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.